Biopharmaceutical aspects of lipid formulations of amphotericin B

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 1, 1997, Pages 64-73

  Storm, G ^a   Van Etten, E ^b  

^a UTRECHT UNIVERSITY   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DRUG CARRIER; LIPID; LIPOSOME;

COLLOID; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; MYCOSIS; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; BIOPHARMACEUTICS; DRUG CARRIERS; HUMANS; LIPIDS; LIPOSOMES;

EID: 0031051913     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01575123     Document Type: Conference Paper

References (63)

1. Pfaller MA: Epidemiology and control of fungal infections. Clinical Infectious Diseases 1994, 19, Supplement 1: 8-13.
2. Szoka FC, Tang M: Amphotericin B formulated in liposomes and lipid based systems: a review. Journal of Liposome Research 1993, 3: 363-375.
3. Gallis HA, Drew RH, Pickard WW: Amphotericin B: 30 years of clinical experience. Reviews of Infectious Diseases 1990, 12: 308-329.
4. Van Etten EWM: Liposomal amphotericin B for invasive fungal infections. An experimental study in the leukopenic host. Doctoral dissertation. Erasmus University Rotterdam, Rotterdam, The Netherlands 1995, p. 9-38.
5. New RPC, Chance ML, Heath J: Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes. Journal of Antimicrobial Chemotherapy 1981, 8: 371-381.
6. Taylor RL, Williams DM, Craven PC, Graybill JR, Drutz DJ, Magee WE: Amphotericin B in liposomes: a novel therapy for histoplasmosis. Annual Review of Respiratory Diseases 1982, 125: 610-611.
7. Graybill JR, Craven PC, Taylor RL, Williams DM, Magee WE: Treatment of murine cryptococcosis with liposome-associated amphotericin B. Journal of Infectious Diseases 1982, 145: 748-752.
8. Lopez-Berestein G, Mehta R, Hopfer RL, Mills K, Kasi L, Mehta K, Fainstein V, Luna W, Hersh EM, Juliano RL: Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome encapsulated amphotericin B. Journal of Infectious Diseases 1983, 147: 939-945.
9. Lopez-Berestein G, Fainstein V, Hopfer RL, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM, Reuben J, Juliano RL, Bodey GP: Liposomal amphotericin B for treatment of systemic fungal infections in patients with cancer: a preliminary study. Journal of Infectious Diseases 1985, 151: 704-710.
10. Lopez-Berestein G, Bodey GP, Fainstain V, Keating M, Frankel LS, Zeluff B, Gentry L, Mehta K: Treatment of systemic fungal infections with liposomal amphotericin B. Archives of Internal Medicine 1989, 149: 2533-2536.
11. De Marie S, Janknegt R, Bakker-Woudenberg IAJM: Clinical use of liposomal and lipid-complexed amphotericin B. Journal of Antimicrobial Chemotherapy 1994, 33: 907-916.
12. Crommelin DJA, Storm G: Drug targeting. In: Sammes PG, Taylor JD (ed): Comprehensive medicinal chemistry. Pergamon, Oxford, 1990, p. 661-701.
13. Storm G, Oussoren C, Peeters RAM, Barenholz Y: Tolerability of liposomes in vivo. In: Gregoriadis G (ed): Liposome technology, Volume III. CRC Press, Boca Raton, FL, 1993, p. 345-383.
14. Talsma H, Crommelin DJA: Liposomes as drug delivery systems. Part 1. Preparation. BioPharm 1992, 5: 36-47.
15. Gregoriadis G (ed): Liposome technology, Volumes I-III. CRC Press, Boca Raton, FL, 1993.
16. Gregoriadis G (ed): Liposome technology, Volumes I-III. CRC Press, Boca Raton, FL, 1984.
17. Gregoriadis G (ed): Liposomes as drug carriers: recent trends and progress. John Wiley, Chichester, UK, 1988.
18. Lopez-Berestein G, Fidler IJ (ed): Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, New York, 1989.
19. Nässander UK, Storm G, Peeters PAM, Crommelin DJA: Liposomes. In: Chasin M, Langer R (ed): Biodegradable polymers as drug delivery systems. Marcel Dekker, New York, 1990, p. 261-338.
20. Lichtenberg D, Barenholz Y: Liposomes: preparation, characterization and preservation. In: Glick D (ed): Methods of biological analysis. Volume 33. John Wiley, New York, 1988, p. 337-461.
21. Grove CF, Jensen J: Liposome-related U.S. patents. In: Gregoriadis G (ed): Liposome technology, Volume II. CRC Press, Boca Raton, FL, 1993, p. 319-324.
22. Senior J: Fate and behavior of liposomes in vivo: a review of controlling factors. Critical Reviews in Therapeutic Drug Carrier Systems 1987, 3: 123-193.
23. Scherphof GL, Roerdink F, Dijkstra J, Ellens H, De Zanger R, Wisse E: Uptake of liposomes by rat and mouse hepatocytes and Kupffer cells. Biology of the Cell 1983, 47: 47-58.
24. Juliano RL: Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Advanced Drug Delivery Reviews 1988, 2: 31-54.
25. Poznansky MJ, Juliano RL: Biological approaches to the controlled delivery of drugs: a critical review. Pharmacological Reviews 1984, 36: 277-336.
26. Gabizon A, Papahadjopoulos D: Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proceedings of the National Academy of Sciences of the USA, 1988, 85: 6949-6953.
27. Allen TM: Stealth liposomes: avoiding reticuloendothelial uptake. In: Lopez-Berestein G, Fidler IJ (ed): Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, New York, 1989, p. 405-415.
28. Klibanov AL, Huang L: Long-circulating liposomes: developments and perspectives. Journal of Liposome Research 1992, 2: 321-334.
29. Woodle MC, Lasic D: Sterically stabilized liposomes. Biochimica et Biophysica Acta 1992, 1113: 171-199.
30. Torchilin VP, Trubetskoy VS: Which polymers can make nanoparticulate drug carriers long-circulating? Advanced Drug Delivery Reviews 1995, 16: 141-155.
31. Storm G, Belliot SO, Daemen T, Lasic DD: Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Advanced Drug Delivery Reviews 1995, 17: 31-48.
32. Bodor N, Brewster ME: Problems of delivery of drugs to the brain. In: Ihler GM (ed): Methods of drug delivery. Pergamon, Oxford, 1986, p. 153-202.
33. Jain RK: Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. Journal of the National Cancer Institute 1989, 81: 570-576.
34. Jain RK: Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Reviews 1990, 9: 253-266.
35. Morgan JR, Williams LA, Howard C: Technetium-labeled liposome imaging for deep-seated infection. British Journal of Radiology 1985, 58: 35-39.
36. Williams BD, O'Sullivan MM, Saggu GS, Williams KE, Williams LA, Morgan JR: Synovial accumulation of technetium-labeled liposomes in rheumatoid arthritis. Annals of the Rheumatic Diseases 1987, 46: 314-318.
37. Bakker-Woudenberg IAJM, Lokerse AF, Ten Kate MT, Mouton JW, Woodle MC, Storm G: Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae infected lung tissue. Journal of Infectious Diseases 1993, 168: 164-171.
38. Love WG, Kellaway IW, Williams BD: Liposome association with inflammatory tissue. In: Gregoriadis G, Florence AT, Patel HM (ed): Liposomes in drug delivery. Harwood Academic Publishers, Chur, Switzerland 1993, p. 149-188.
39. Gabizon A: Liposome circulation time and tumor targeting: implications for cancer chemotherapy. Advanced Drug Delivery Reviews 1995, 16: 285-294.
40. Gabizon A: Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Research 1992, 52: 891-896.
41. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A: Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. Journal of Clinical Oncology 1995, 13: 1777-1785.
42. Presant GA, Scolaro M, Kenndy R Blayney DW, Flanagan B, Lisak J, Presant J: Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 1993, 341: 1242-1243.
43. Guo LSS, Fielding RM, Lasic DD, Hamilton RL, Mufson D: Novel antifungal drug delivery: stable amphotericin B-cholesteryl sulfate discs. International Journal of Pharmaceutics 1991, 75: 45-54.
44. Janoff AS, Perkins WR, Saletan SL, Swenson CE: Amphotericin B lipid complex (ABLC™): a molecular rationale for the attenuation of amphotericin B related toxicities. Journal of Liposome Research 1993, 3: 451-471.
45. Janknegt R, De Marie S, Bakker-Woudenberg IAJM, Crommelin DJA: Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics. Clinical Pharmacokinetics 1992, 23: 279-291.
46. Storm G, Nassander UK, Steerenberg PA, Roerdink FH, De Jong WH, Crommelin DJA: Studies on the mode of action of doxorubicin-liposomes. In: Fidler IJ, Lopez-Berestein G (ed): Liposomes in the therapy of infectious diseases and cancer. Alan R. Liss, New York, 1989, p. 105-116.
47. Van Etten EWM, Otte Lambillion M, Van Vianen W, Ten Kate MT, Bakker-Woudenberg IAJM: Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans. Journal of Antimicrobial Chemotherapy 1995, 35: 509-519.
48. Gabizon A, Huberty J, Straubinger RM, Price DC, Papahadjopoulos D: An improved method for in vivo tracing and imaging of liposomes using a gallium 67-deferoxamine complex. Journal of Liposome Research 1988-89, 1: 123-135.
49. Wasan KM, Lopez-Berestein G: Modification of amphotericin B's therapeutic index by increasing its association with serum high-density lipoproteins. Annals of the New York Academy of Sciences 1994, 730: 93-106.
50. Juliano RL, Grant CWM, Barber KR, Kalp MA: Mechanism of the selective toxicity of amphotericin B incorporated into liposomes. Molecular Pharmacology 1987, 31: 1-11.
51. Adler-Moore JP, Proffitt RT: Development, characterization, efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. Journal of Liposome Research 1993, 3: 429-450.
52. Perkins WR, Minchey SR, Boni LT, Swenson CE, Popescu MC, Pasternack RF, Janoff AS: Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity. Biochimica et Biophysica Acta 1992, 1107: 271-282.
53. Mehta RT, McQueen TJ, Keyhani A, Lopez-Berestein G: Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Chemotherapy 1994, 40: 256-264.
54. Crommelin DJA, Scherphof G, Storm G: Active targeting with particulate systems in the blood compartment. Advanced Drug Delivery Reviews 1995, 17: 49-60.
55. Belay T, Hospenthal DR, Rogers AL, Patterson MJ: Evaluation of antibody-bearing liposomal amphotericin B in the treatment of systemic candidiasis in a neutropenic murine model. Journal of Medical and Veterinary Mycology 1991, 29: 419-421.
56. Belay T, Hospenthal DR, Rogers AL, Patterson MJ: Treatment of systemic candidiasis in a murine model using immunoglobulin G bearing liposomal amphotericin B. Mycopathologia 1993, 123: 9-17.
57. Dromer F, Barbet J, Bolard J, Charreire J, Yeni P: Improvement of amphotericin B activity during experimental cryptococcosis by incorporating into immunoliposomes. Antimicrobial Agents and Chemotherapy 1990, 34: 2055-2060.
58. Hospenthal D, Gretzinger K, Rogers A: Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to Candida albicans. Journal of Medical Microbiology 1989, 30: 193-197.
59. Hospenthal DR, Rogers AL, Beneke ES: Effect of attachment of anticandidal antibody to the surface of liposomes encapsulating amphotericin B in the treatment of murine candidiasis. Antimicrobial Agents and Chemotherapy 1989, 33: 16-18.
60. Bakker-Woudenberg IAJM, Lokerse AF, Ten Kate MT, Mouton JW, Woodle MC, Storm G: Liposomes with prolonged blood circulation and selective localization in Klebsiella pneumoniae-infected lung tissue. Journal of Infectious Diseases 1993, 168: 164-171.
61. Bakker-Woudenberg IAJM, Ten Kate MT, Stearne-Cullen LET, Woodle MC: Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue. Journal of Infectious Diseases 1995, 171: 938-947.
62. Boerman OC, Storm G, Oyen WJG, Van Bloois L, Van der Meer JWM, Ciaessens RAMJ, Crommelin DJA, Corstens FHM: Sterically stabilized liposomes labeled with Indium-111 to image focal infection. Journal of Nuclear Medicine 1995, 36: 1639-1644.
63. Van Etten EWM, Ten Kate MT, Stearne-Cullen LET, Bakker-Woudenberg IAJM: Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice. Antimicrobial Agents and Chemotherapy 1995, 39: 1954-1958.